Study to Evaluate the Efficacy and Safety of Glycopyrronium or Indacaterol Maleate and Glycopyrronium Bromide Fixed-dose Combination Regarding Symptoms and Health Status in Patients With Moderate COPD Switching From Treatment With Any Standard COPD Regimen

NCT01985334 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

4389

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD

Interventions

DRUG: Glycopyrronium
DRUG: SABA
DRUG: LABA
DRUG: Indacaterol maleate and glycopyrronium bromide
DRUG: LAMA
DRUG: SAMA
DRUG: ICS

Sponsor

Novartis Pharmaceuticals